Urogen Pharma (URGN) Projected to Post Earnings on Wednesday

Urogen Pharma (NASDAQ:URGN) is projected to announce its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.2650) per share and revenue of $63.5460 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 10:00 AM ET.

Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Thursday, May 7th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.01. The business had revenue of $50.96 million for the quarter, compared to the consensus estimate of $44.83 million. On average, analysts expect Urogen Pharma to post $-1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Urogen Pharma Stock Performance

URGN stock opened at $38.24 on Monday. The business’s 50 day simple moving average is $34.98 and its 200 day simple moving average is $26.33. Urogen Pharma has a 1-year low of $15.86 and a 1-year high of $43.93. The firm has a market capitalization of $1.86 billion, a PE ratio of -13.91 and a beta of 1.57.

Insider Transactions at Urogen Pharma

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the transaction, the insider owned 119,763 shares in the company, valued at $4,790,520. This represents a 7.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 25,222 shares of company stock valued at $892,661. Insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On Urogen Pharma

Large investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Urogen Pharma by 7.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock valued at $258,000 after acquiring an additional 1,653 shares in the last quarter. Main Street Financial Solutions LLC increased its position in shares of Urogen Pharma by 8.2% in the second quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company’s stock worth $356,000 after purchasing an additional 1,968 shares during the period. Barclays PLC increased its position in shares of Urogen Pharma by 3.8% in the fourth quarter. Barclays PLC now owns 57,744 shares of the company’s stock worth $1,352,000 after purchasing an additional 2,125 shares during the period. Osaic Holdings Inc. raised its stake in Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after purchasing an additional 3,070 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its position in Urogen Pharma by 1,594.4% during the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after purchasing an additional 3,125 shares during the period. Institutional investors and hedge funds own 91.29% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. UBS Group reiterated a “buy” rating on shares of Urogen Pharma in a report on Thursday, July 9th. HC Wainwright reissued a “buy” rating on shares of Urogen Pharma in a report on Thursday, July 9th. Jefferies Financial Group raised Urogen Pharma to a “strong-buy” rating in a research report on Friday, April 24th. Guggenheim increased their target price on Urogen Pharma from $32.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $41.62.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.